^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CM93

    i
    Other names: CM93
    Associations

    News

    Trials
    Company:
    Crimson Biopharm
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Crimson Biopharm Inc. | Trial completion date: Jul 2028 --> Jul 2029 | Trial primary completion date: Jul 2027 --> Jul 2029
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    CM93
    over1year
    CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Crimson Biopharm Inc. | Trial completion date: Jul 2024 --> Jul 2028 | Trial primary completion date: Jul 2023 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR amplification • IDH wild-type
    |
    CM93
    over3years
    CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Crimson Biopharm Inc.
    Clinical • New P1 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR amplification
    |
    CM93